Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Metacrine’s Shift Means Further Attrition In FXR Agonist Class For NASH
Oct 25 2021
•
By
Joseph Haas
Metacrine is changing course to a focus on IBD, rather than NASH
More from Strategy
More from Business